ArticleFrontiers in oncology2020
Noninvasive Detection of Extracellular pH in Human Benign and Malignant Liver Tumors Using CEST MRI.
Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 49 citations in OpenAlex.
- Article
- Peptide-Based pH-Responsive MRI-CEST Agents: In Vivo Comparison between a Selected Pentapeptide and the Established Iopamidol Reference in Tumor pH Mapping Ability.Chemical & biomedical imaging · 2026Article
- Developing a Clinically Practical Biomaterial Platform for Endogenous Liver Regeneration.Gels (Basel, Switzerland) · 2026Review
- Brain Tumor Imaging with Iopamidol CEST MRI: In Vivo Detection and Validation.Chemical & biomedical imaging · 2026Article
- Overcoming tumor microenvironment barriers: transformable and bioinspired nanomedicine strategies for deep tumor penetration.Journal of nanobiotechnology · 2026Review
- The Evolving Landscape of Hepatocellular Carcinoma Therapy: From Conventional Modalities to TME-Responsive Prodrug Design Strategies.Drug design, development and therapy · 2026Review
- The acidic tumor microenvironment in hepatocellular carcinoma: a barrier to adoptive cellular immunotherapy.Frontiers in immunology · 2026Review
- Human liver CEST imaging at 7 T: Impact ofMagnetic resonance in medicine · 2025Article
- Glucose stimulated CEST MRI pHe mapping for improved differentiation of tumors with altered hypoxia inducible factor 1alpha expression.Scientific reports · 2025Article
- Inflammatory microenvironment-responsive MR imaging contrast agents.Nanomedicine (London, England) · 2025Review
- Novel non‑metal‑based contrast agents for MR imaging: Emerging approaches and clinical perspectives (Review).International journal of oncology · 2025Review
- Design Chemical Exchange Saturation Transfer Contrast Agents and Nanocarriers for Imaging Proton ExchangeACS nano · 2024Review
- Development and Validation of Four Different Methods to Improve MRI-CEST Tumor pH Mapping in Presence of Fat.Journal of imaging · 2024Article
- Multiparametric MRI for characterization of the tumour microenvironment.Nature reviews. Clinical oncology · 2024Review
- An Update on MR Spectroscopy in Cancer Management: Advances in Instrumentation, Acquisition, and Analysis.Radiology. Imaging cancer · 2024Review
- L-DOS47 Elevates Pancreatic Cancer Tumor pH and Enhances Response to Immunotherapy.Biomedicines · 2024Article
- Multiparametric quantitative MRI of healthy adult pancreas: correlations with gender and age.Frontiers in gastroenterology (Lausanne, Switzerland) · 2024Article
- A machine learning approach that measures pH using acidoCEST MRI of iopamidol.NMR in biomedicine · 2023Article
- Simultaneous magnetic resonance imaging of pH, perfusion and renal filtration using hyperpolarizedNature communications · 2023Article
- Intracellular Acidification in a Rat C6 Glioma Model following Cariporide Injection Investigated by CEST-MRI.Metabolites · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIn this study, we aimed to use 3T magnetic resonance imaging (MRI), which is clinically available, to determine the extracellular pH (pHe) of liver tumors and prospectively evaluate the ability of chemical exchange saturation transfer (CEST) MRI to distinguish between benign and malignant liver tumors.
methodsDifferent radiofrequency irradiation schemes were assessed for ioversol-based pH measurements at 3T. CEST effects were quantified
resultsBy conducting dual-power CEST MRI, the pH of solutions was determined to be 6.0-7.2 at 3T
conclusiondual-power CEST MRI can detect extracellular pH in human liver tumors and can provide molecular-level diagnostic tools for differentiating benign and malignant liver tumors at 3T.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.